AlloVir Investor Relations Material

AlloVir, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, virus-specific T cell (VST) therapies. Its proprietary platform enables the creation of off-the-shelf VSTs designed to prevent and treat severe viral diseases, particularly in patients with compromised immune systems. The company's lead product candidate, posoleucel, targets multiple viruses, including adenovirus, cytomegalovirus, and Epstein-Barr virus. AlloVir's pipeline also includes therapies in development for respiratory and other viral infections. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.